Clinical Trial Update: Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer [Phase 1]

View source ↗

Summary

A Phase 1b clinical trial is planned to evaluate a triple combination of Avutometinib, Defactinib, and Everolimus in patients with endometrial cancer harboring …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)
• Everolimus (everolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase IB, Avutometinib | Phase 1 | Status: NOT_YET_RECRUITING